SuperworthOvid Therapeutics shares outstanding OVID
Diluted shares outstanding, averaged over each quarter, from 2016.
- Latest quarter, to Jun 30, 2026
- 197.5M
- On a year earlier
- +177.7%
- more shares
Ovid Therapeutics had 197.5M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 177.7% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 81.6M | +15% |
| FY2024 | 71M | +0% |
| FY2023 | 70.7M | +0% |
| FY2022 | 70.5M | +4% |
| FY2021 | 68.1M | +6% |
| FY2020 | 64M | +160% |
| FY2018 | 24.7M | +0% |
| FY2017 | 24.6M | +150% |
| FY2016 | 9.8M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 197.5M | +178% | |
| Q1 FY26 | 136.2M | +92% | |
| Q4 FY25 | 81.6M | +15% | |
| Q3 FY25 | 71.1M | +0% | |
| Q2 FY25 | 71.1M | −0% | |
| Q1 FY25 | 71M | +0% | |
| Q4 FY24 | 71M | +0% | |
| Q3 FY24 | 71M | +1% | |
| Q2 FY24 | 71.2M | +1% | |
| Q1 FY24 | 70.7M | +0% | |
| Q4 FY23 | 70.7M | +0% | |
| Q3 FY23 | 70.6M | +0% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Ovid Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.